Irvine-based enVVeno Medical Corp. today announced several clinical updates in its second quarter earnings today.
During the second quarter, the company received FDA investigational device exemption (IDE) approval to begin a U.S. pivotal study for its enVVee system, which is a minimally invasive replacement venous valve for patients suffering from severe deep chronic venous insufficiency (CVI).
The trial is expected to start later this year and enroll approximately 230 patients across 40 clinical sites, according to enVVeno.
The company ended the quarter with $21.5 million in cash and investments, which it said will fund operations into the third quarter of 2027.
Shares in enVVeno were little changed at $10.63 and a $7 million market cap (Nadaq: NVNO).